Table 2.
Contraindications for intravenous recombinant tissue plasminogen activator (rtPA) in acute ischemic stroke
| Contraindications applicable to use of intravenous rtPA in acute ischemic stroke (AIS) | 
| Onset of stroke symptoms more than 4.5 h.Ψ | 
| History of stroke or significant head trauma in previous 3 months | 
| Previous intracranial haemorrhage. | 
| Symptoms are suggestive of subarachnoid haemorrhage. | 
| Prolonged blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg). | 
| Hypoglycemia (serum glucose <50 mg/dL (<2.8 mmol/L)). | 
| Active internal bleeding, acute bleeding diathesis, including platelet count <100, 000/mm3, current anticoagulant use with an INR > 1.7, or PT > 15 s. | 
| Heparin use within 48 h with an abnormally elevated aPTT. | 
| Arterial puncture at noncompressible site in previous 7 days. | 
| History of gastrointestinal tract haemorrhage within 21 days. | 
| The recent history of major surgery intracranial or intraspinal surgery within 14 days. | 
| Previous history of a previous aneurysm, arteriovenous malformation, or intracranial neoplasm. | 
| Current use of a direct thrombin inhibitor or direct factor Xa inhibitors with an evidence of anticoagulation effect by laboratory tests such as aPTT, INR < ECT, TT, or relevant factor Xa activity assays. | 
| Early ischemic changes are visible on CT in more than one-third of MCA artery vascular territory consistent with irreversible injury or evidence of haemorrhage on CT scan. | 
ΨAdditional criteria applicable for IV-rtPA between 3 to 4.5 h: patient older than 80 years, severe stroke (baseline NIHSS >25), no prior history of diabetes mellitus and AIS (both), and not currently on any oral anticoagulants regardless of INR.
CT Computed tomography; INR International normalised ratio; IV-rtPA Intravenous recombinant tissue plasminogen activator; MCA Middle cerebral artery; NIHSS National Institute of Health Stroke Scale; PT Prothrombin time; aPTT Activated partial thromboplastin time; ECT Ecarin clotting time